LEXICON PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2011-12-31 was $0.00, a 100.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2011-09-30 was $1.00K.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2010-12-31 was $5.00K.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2010-09-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2011 was $189.00K, a 759.09% increase from fiscal 2010.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2010 was $22.00K, a 91.67% decline from fiscal 2009.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2009 was $264.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-08 | $189.00K 10-K · filed 2012-03-08 |
| 2011-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | |
| 2010-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-08 | $22.00K 10-K · filed 2012-03-08 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | |
| 2009-12-31 | $264.00K 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |